Chronic Myeloproliferative Neoplasm Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Chronic kidney disease and thrombotic risk in patients with chronic myeloproliferative neoplasms
(Source: Journal of Thrombosis and Thrombolysis)
Source: Journal of Thrombosis and Thrombolysis - February 6, 2023 Category: Hematology Source Type: research

Cancers, Vol. 14, Pages 5495: Recombinant Interferon- & beta; in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives
Cancers, Vol. 14, Pages 5495: Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives Cancers doi: 10.3390/cancers14225495 Authors: Hans Hasselbalch Vibe Skov Lasse Kjær Morten Kranker Larsen Trine A. Knudsen Marko Lucijanić Rajko Kusec About 30 years ago, the first clinical trials of the safety and efficacy of recombinant interferon-&alpha;2 (rIFN-&alpha;2) were performed. Since then, several single-arm studies have shown rIFN-&alpha;2 to be a highly potent anticancer agent against several cancer types. Unfortu...
Source: Cancers - November 9, 2022 Category: Cancer & Oncology Authors: Hans Hasselbalch Vibe Skov Lasse Kj ær Morten Kranker Larsen Trine A. Knudsen Marko Lucijani ć Rajko Kusec Tags: Perspective Source Type: research

Transplantation algorithm for myelofibrosis in 2022 and beyond
Best Pract Res Clin Haematol. 2022 Jun;35(2):101369. doi: 10.1016/j.beha.2022.101369. Epub 2022 Aug 3.ABSTRACTMyelofibrosis (MF) is a chronic myeloproliferative neoplasm with a very heterogenous clinical course. Median survival of patients with overt MF is close to 6 years, but with great individual variability. Allogeneic hematopoietic cell transplantation (allo-HCT) constitutes the only curative treatment, yet the advanced age of MF patients, together with significant transplant-related mortality, limit the applicability of this procedure in clinical practice to less than 10% of patients. In this article, we review the c...
Source: Cell Research - November 4, 2022 Category: Cytology Authors: Juan-Carlos Hern ández-Boluda Tomasz Czerw Source Type: research

MPN-541 Estimated Plasma Volume Status in Patients With Primary Myelofibrosis and Associated Thrombotic and Mortality Risks
Context: Blood plasma experiences substantial changes in both volume and composition in patients with chronic myeloproliferative neoplasms (MPN) and represents a large reservoir of cytokines and other mediators of inflammation. Higher estimated plasma volume status (ePVS) has recently been shown to correlate with increased thrombotic risk in polycythemia vera patients. Objective: To estimate clinical and prognostic associations of ePVS in patients with myelofibrosis. Design: Retrospective cohort study. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 21, 2022 Category: Hematology Authors: Marko Lucijanic, Ivan Krecak, Ena Soric, Anica Sabljic, Davor Galusic, Hrvoje Holik, Vlatka Perisa, Martina Moric Peric, Ivan Zekanovic, Rajko Kusec Tags: Myeloproliferative Neoplasms Source Type: research

Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients
This study depicts conditional probabilities of having detectable antibodies in the whole cohort and in specific scenarios such as B cell NHL, CLL, MM, and cMPN that may impact humoral responses. These results could be useful to focus on additional preventive and/or monitoring interventions in these highly immunosuppressed hemato logical patients. (Source: Annals of Hematology)
Source: Annals of Hematology - August 19, 2022 Category: Hematology Source Type: research

Transformation from polycythemia vera to acute promyelocytic leukemia: Case report and literature review
Conclusion: Polycythemia vera can transform into acute promyelocytic leukemia; therefore, it is important to review bone aspiration and other tests to perform a comprehensive assessment and monitor the disease status, to detect disease progression and intervene early when it transforms into acute promyelocytic leukemia. (Source: Medicine)
Source: Medicine - August 12, 2022 Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research

Impact of molecular profiling on the management of patients with myelofibrosis
Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) that appears de novo (primary myelofibrosis, PMF) or develops from a prior polycythemia vera (PV) or essential thrombocythemia (ET) [secondary myelofibrosis, SMF]. The disease originates from a pluripotent hematopoietic stem cell whose clonal proliferation is accompanied by inappropriate release of cytokines and growth factors which induce bone marrow fibrosis and extramedullary hematopoiesis, usually resulting in splenomegaly [1]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - July 7, 2022 Category: Cancer & Oncology Authors: Irene Pastor-Gal án, Iván Martín, Blanca Ferrer, Juan-Carlos Hernández-Boluda Source Type: research

Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients
This study depicts conditional probabilities of having detectable antibodies in the whole cohort and in specific scenarios such as B cell NHL, CLL, MM, and cMPN that may impact humoral responses. These results could be useful to focus on additional preventive and/or monitoring interventions in these highly immunosuppressed hemato logical patients. (Source: Annals of Hematology)
Source: Annals of Hematology - July 2, 2022 Category: Hematology Source Type: research

Splenic Infarct as the Presenting Manifestation of Essential Thrombocythemia
Conclusion: Our patient had an undiagnosed case of essential thrombocythemia and presented with symptoms related to splenic infarction. To the best of our knowledge, few cases of splenic infarction consequent to essential thrombocythemia have been reported.PMID:35756582 | PMC:PMC9196959 | DOI:10.31486/toj.21.0073 (Source: Ochsner Journal)
Source: Ochsner Journal - June 27, 2022 Category: General Medicine Authors: Shalaka Khade Sudeep Khera Vaibhav Kumar Varshney Deepak Kumar Sharma Raghav Nayar Abhishek Purohit Source Type: research